An exploratory study of metformin and rapamycin as maintenance therapy

Volume 11

,

Number 21

of

@Oncotarget

reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with

rapamycin

, stratified by prior treatment with

FOLFIRINOX

. Metformin +/ rapamycin maintenance for

mPDA

was well-tolerated and several patients achieved stable disease associated with exceptionally long survival.

Dr. Dung T. Le from

The Sidney Kimmel Comprehensive Cancer Center

at Johns Hopkins, Baltimore, MD, 21287 said, ”

Pancreatic ductal adenocarcinoma

(PDA) is aggressive cancer with high mortality at all stages and limited treatment options in the advanced setting.”

Metformin

is an antidiabetic drug in the biguanide class of agents which inhibits

mTOR

complex 1 primarily through AMP-kinase activation.

A synergistic effect of the combination of metformin with rapamycin was suggested by preclinical studies demonstrating enhanced inhibition of mTOR in a pancreatic cancer cell line and better growth inhibition of pancreatic cancer cells in a

xenograft

tumor model with the combination than either agent alone.

Based on this, they conducted an exploratory study of metformin with or without rapamycin in patients with mPDA in the maintenance setting.

The Le Research Team concluded in their


Oncotarget



Research Article

, “the administration of metformin with or without rapamycin in patients with mPDA who achieve a response to

chemotherapy

is well-tolerated and was associated with better than expected overall survival in this study. Additional studies are needed to prospectively evaluate the role of these agents compared to a maintenance chemotherapy or observation only approach.”

###

Sign up for free Altmetric alerts about this article

DOI –

https:/

/

doi.

org/

10.

18632/

oncotarget.

27539

Full text –

https:/

/

www.

oncotarget.

com/

article/

27586/

text/

Correspondence to – Dung T. Le –

[email protected]

Keywords – pancreatic cancer, mTOR inhibition, maintenance therapy, metformin

About

Oncotarget

Oncotarget

is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about

Oncotarget

, please visit

https:/

/

www.

oncotarget.

com

or connect with:

SoundCloud –

https:/

/

soundcloud.

com/

oncotarget


Facebook –

https:/

/

www.

facebook.

com/

Oncotarget/

Twitter –

https:/

/

twitter.

com/

oncotarget


LinkedIn –

https:/

/

www.

linkedin.

com/

company/

oncotarget


Pinterest –

https:/

/

www.

pinterest.

com/

oncotarget/

Reddit –

https:/

/

www.

reddit.

com/

user/

Oncotarget/

Oncotarget

is published by Impact Journals, LLC please visit

http://www.

ImpactJournals.

com

or connect with @ImpactJrnls

Media Contact



[email protected]


18009220957×105